Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1981 1
1983 1
1989 1
1991 1
1993 1
1999 1
2010 1
2011 1
2012 1
2014 2
2015 2
2018 1
2019 1
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Cryoprecipitate: an outmoded treatment?
Yang L, Stanworth S, Baglin T. Yang L, et al. Transfus Med. 2012 Oct;22(5):315-20. doi: 10.1111/j.1365-3148.2012.01181.x. Transfus Med. 2012. PMID: 22994448 Review.
Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vWF), fibrinogen, fibronectin and factor XIII. Its use was first described in the 1960s for treatment of patients with factor …
Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vW …
Current challenges in the management of hemophilia.
Bauer KA. Bauer KA. Am J Manag Care. 2015 Mar;21(6 Suppl):S112-22. Am J Manag Care. 2015. PMID: 26168206 Free article. Review.
Hemophilia is characterized by genetic mutations resulting in the deficiency of factors critical to the normal process of coagulation, sometimes resulting in spontaneous bleeding into soft tissue, joints, and internal organs. The 2 most common subtypes are hemophilia A, or …
Hemophilia is characterized by genetic mutations resulting in the deficiency of factors critical to the normal process of coagulation …
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Mancuso ME, Mahlangu JN, Pipe SW. Mancuso ME, et al. Lancet. 2021 Feb 13;397(10274):630-640. doi: 10.1016/S0140-6736(20)32722-7. Epub 2021 Jan 15. Lancet. 2021. PMID: 33460559 Review.
Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. ...However, replacement therapy is associated with a risk for inhibitor development that adversely affects bleeding prevention …
Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding diso …
Practices and challenges for hemophilia management under resource constraints in Thailand.
Moonla C, Sosothikul D, Pongtanakul B, Suwanawiboon B, Traivaree C, Natesirinilkul R, Sirachainan N, Angchaisuksiri P. Moonla C, et al. Orphanet J Rare Dis. 2023 May 10;18(1):110. doi: 10.1186/s13023-023-02718-1. Orphanet J Rare Dis. 2023. PMID: 37161533 Free PMC article.
Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor. Factor VIII deficiency is responsible for hemophilia A while factor IX deficiency is responsible for hemophilia B. ...Despite the c …
Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor. Factor VIII …
Gene therapy in an era of emerging treatment options for hemophilia B.
Monahan PE. Monahan PE. J Thromb Haemost. 2015 Jun;13 Suppl 1(0 1):S151-60. doi: 10.1111/jth.12957. J Thromb Haemost. 2015. PMID: 26149016 Free PMC article. Review.
Factor IX deficiency (hemophilia B) is less common than factor VIII deficiency (hemophilia A), and innovations in therapy for hemophilia B have generally lagged behind those for hemophilia A. Recently, the first sustained correction of th …
Factor IX deficiency (hemophilia B) is less common than factor VIII deficiency (hemophilia A), and innova …
von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment.
Pacheco LD, Costantine MM, Saade GR, Mucowski S, Hankins GD, Sciscione AC. Pacheco LD, et al. Am J Obstet Gynecol. 2010 Sep;203(3):194-200. doi: 10.1016/j.ajog.2010.02.036. Epub 2010 Apr 24. Am J Obstet Gynecol. 2010. PMID: 20417473 Review.
von Willebrand disease is caused by either a quantitative or qualitative defect in von Willebrand factor (VWF). Patients may have extensive mucosal bleeding (because of platelet dysfunction) and prolonged bleeding after surgery (because of factor VIII defi …
von Willebrand disease is caused by either a quantitative or qualitative defect in von Willebrand factor (VWF). Patients may have ext …
"Haemophilia A" - Presenting with oral squamous cell carcinoma diagnosis and management strategies.
K P A, Thakur S, Hanagvadi S, Siva Bharani KSN. K P A, et al. Oral Oncol. 2022 Sep;132:105994. doi: 10.1016/j.oraloncology.2022.105994. Epub 2022 Jul 1. Oral Oncol. 2022. PMID: 35785746
Hemophilia is a hereditary disorder of coagulation that results in deficiency of factor VIII (Hemophilia A) or Factor IX (Hemophilia B) with characteristic X linked mode of inheritance, almost exclusively seen in males while females are asymptomatic ca …
Hemophilia is a hereditary disorder of coagulation that results in deficiency of factor VIII (Hemophilia A) or Facto …
Turoctocog alfa for the treatment of hemophilia A.
Haddley K. Haddley K. Drugs Today (Barc). 2014 Feb;50(2):121-31. doi: 10.1358/dot.2014.50.2.2116671. Drugs Today (Barc). 2014. PMID: 24619589 Review.
Patients with hemophilia A lack functional coagulation factor VIII (FVIII), causing excessive spontaneous bleeding episodes and bleeding during trauma or surgery. ...
Patients with hemophilia A lack functional coagulation factor VIII (FVIII), causing excessive spontaneous bleeding episodes an …
Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis.
Esteves Pereira M, Bocksrucker C, Kremer Hovinga JA, Mueller M, Daskalakis M, Mansouri Taleghani B, Nagler M. Esteves Pereira M, et al. Transfus Med Rev. 2021 Apr;35(2):125-134. doi: 10.1016/j.tmrv.2021.01.001. Epub 2021 Jan 12. Transfus Med Rev. 2021. PMID: 33518429 Free article. Review.
Even though immunoadsorption (IA) rapidly removes autoantibodies against factor VIII, this intervention's effectiveness is still a matter of debate. ...Within our institution, 12 patients have been treated since 2002; median age was 76 years (range 34-86); median ti …
Even though immunoadsorption (IA) rapidly removes autoantibodies against factor VIII, this intervention's effectiveness is sti …
Congenital bleeding disorders. Rational treatment options.
Seremetis SV, Aledort LM. Seremetis SV, et al. Drugs. 1993 Apr;45(4):541-7. doi: 10.2165/00003495-199345040-00006. Drugs. 1993. PMID: 7684674 Review.
All currently available products for patients with haemophilia A (factor VIII deficiency) are comparable in terms of efficacy and viral safety. ...In the treatment of haemophilia B (factor IX deficiency), purified factor IX concentrates a …
All currently available products for patients with haemophilia A (factor VIII deficiency) are comparable in terms of ef …
20 results